1. B-lymphocyte-activating factor is a potential biomarker associated with susceptibility to Graves’ disease in Iraqi women
- Author
-
Hiba Y. Ibrahim, Ghassan M. Sulaiman, Ali H. Ad’hiah, and Mohamed S. Al-shammaa
- Subjects
Graves’ disease ,B-lymphocyte-activating factor ,Vitamin D ,rs9514827 ,rs9514828 ,Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
Abstract Background B-lymphocyte-activating factor (BAFF) is a cytokine involved in regulating the development and maturation of B lymphocyte and has been shown to be up-regulated in patients with Graves’ disease (GD). However, the association of TNFSF13B variants (the gene that encodes BAFF) with the risk of GD has not been well explored. In this case–control study, the aim was to evaluate the role of BAFF, in terms of serum level and polymorphism, in the etio-pathogenesis of GD. Therefore, serum BAFF concentrations were analyzed in Iraqi women with GD and age-matched control women (n = 90 and 93, respectively) using an ELISA kit. In addition, two promoter variants of the TNFSF13B gene, rs9514827 (T > C) and rs9514828 (C > T), were genotyped using a PCR–RFLP-based assay. Results Median BAFF concentrations (interquartile range) were significantly elevated in GD patients compared to controls (1525 [1327–1840] vs. 689 [585–807] pg/mL; probability [p]
- Published
- 2023
- Full Text
- View/download PDF